Miastenia gravis juvenil

Translated title of the contribution: Juvenile myasthenia gravis

Oscar Papazian, Israel Alfonso, Nayle Araguez

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Juvenile myasthenia gravis is a chronic autoimmune disorder which occurs when serum antibodies combine with nicotinic acetylcholine receptors at the muscle membrane of the motor endplate imparing the neuromuscular transmission. It results in early muscle fatigability with progression to a complete paralysis during repetitive muscle contraction (movements) or steady muscle contraction (postures), and less common persistent paralysis at rest. The cranial nerves, mainly the one innervating the extraoccular and palpebral levator, are the most susceptible to permanent weakness and paralysis at rest. Initial clinical presentations are generalized, ocular and respiratory forms. The diagnosis is suspected through medical history of abnormal fatigability and corroborated by physical examination, repetitive nerve stimulation of an affected but not complete paralyzed muscle, correction of fatigability by the intravenous administration of acetylcholine esterase inhibitors, and by the presence of serum acetylcholine receptors antibodies (ACRA). The long term treatment is symptomatic (acetylcholine inhibitors) and etiopathogenic (immunosupresor drugs, plasmapheresis, intravenous gamma globulin and thymectomy. Spontaneous or post symptomatic and etiopathogenic treatment remissions occur from 1 to 10 years. Fatality is rare but children are at high risk during myasthenia crisis.

Original languageSpanish
Pages (from-to)71-83
Number of pages13
JournalMedicina
Volume69
Issue number1 PART 1
StatePublished - Mar 18 2009

Fingerprint

Myasthenia Gravis
Paralysis
Muscle Contraction
Muscles
Acetylcholine
Motor Endplate
Thymectomy
Plasmapheresis
Cranial Nerves
Antibodies
gamma-Globulins
Nicotinic Receptors
Cholinergic Receptors
Eyelids
Esterases
Serum
Posture
Intravenous Administration
Physical Examination
Membranes

Keywords

  • ACRA
  • Diagnosis
  • Myasthenia gravis
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Papazian, O., Alfonso, I., & Araguez, N. (2009). Miastenia gravis juvenil. Medicina, 69(1 PART 1), 71-83.

Miastenia gravis juvenil. / Papazian, Oscar; Alfonso, Israel; Araguez, Nayle.

In: Medicina, Vol. 69, No. 1 PART 1, 18.03.2009, p. 71-83.

Research output: Contribution to journalArticle

Papazian, O, Alfonso, I & Araguez, N 2009, 'Miastenia gravis juvenil', Medicina, vol. 69, no. 1 PART 1, pp. 71-83.
Papazian O, Alfonso I, Araguez N. Miastenia gravis juvenil. Medicina. 2009 Mar 18;69(1 PART 1):71-83.
Papazian, Oscar ; Alfonso, Israel ; Araguez, Nayle. / Miastenia gravis juvenil. In: Medicina. 2009 ; Vol. 69, No. 1 PART 1. pp. 71-83.
@article{f56b2b84bc574c3088d8adfabcce9492,
title = "Miastenia gravis juvenil",
abstract = "Juvenile myasthenia gravis is a chronic autoimmune disorder which occurs when serum antibodies combine with nicotinic acetylcholine receptors at the muscle membrane of the motor endplate imparing the neuromuscular transmission. It results in early muscle fatigability with progression to a complete paralysis during repetitive muscle contraction (movements) or steady muscle contraction (postures), and less common persistent paralysis at rest. The cranial nerves, mainly the one innervating the extraoccular and palpebral levator, are the most susceptible to permanent weakness and paralysis at rest. Initial clinical presentations are generalized, ocular and respiratory forms. The diagnosis is suspected through medical history of abnormal fatigability and corroborated by physical examination, repetitive nerve stimulation of an affected but not complete paralyzed muscle, correction of fatigability by the intravenous administration of acetylcholine esterase inhibitors, and by the presence of serum acetylcholine receptors antibodies (ACRA). The long term treatment is symptomatic (acetylcholine inhibitors) and etiopathogenic (immunosupresor drugs, plasmapheresis, intravenous gamma globulin and thymectomy. Spontaneous or post symptomatic and etiopathogenic treatment remissions occur from 1 to 10 years. Fatality is rare but children are at high risk during myasthenia crisis.",
keywords = "ACRA, Diagnosis, Myasthenia gravis, Treatment",
author = "Oscar Papazian and Israel Alfonso and Nayle Araguez",
year = "2009",
month = "3",
day = "18",
language = "Spanish",
volume = "69",
pages = "71--83",
journal = "Medicina",
issn = "0025-7680",
publisher = "Instituto de Investigaciones Medicas",
number = "1 PART 1",

}

TY - JOUR

T1 - Miastenia gravis juvenil

AU - Papazian, Oscar

AU - Alfonso, Israel

AU - Araguez, Nayle

PY - 2009/3/18

Y1 - 2009/3/18

N2 - Juvenile myasthenia gravis is a chronic autoimmune disorder which occurs when serum antibodies combine with nicotinic acetylcholine receptors at the muscle membrane of the motor endplate imparing the neuromuscular transmission. It results in early muscle fatigability with progression to a complete paralysis during repetitive muscle contraction (movements) or steady muscle contraction (postures), and less common persistent paralysis at rest. The cranial nerves, mainly the one innervating the extraoccular and palpebral levator, are the most susceptible to permanent weakness and paralysis at rest. Initial clinical presentations are generalized, ocular and respiratory forms. The diagnosis is suspected through medical history of abnormal fatigability and corroborated by physical examination, repetitive nerve stimulation of an affected but not complete paralyzed muscle, correction of fatigability by the intravenous administration of acetylcholine esterase inhibitors, and by the presence of serum acetylcholine receptors antibodies (ACRA). The long term treatment is symptomatic (acetylcholine inhibitors) and etiopathogenic (immunosupresor drugs, plasmapheresis, intravenous gamma globulin and thymectomy. Spontaneous or post symptomatic and etiopathogenic treatment remissions occur from 1 to 10 years. Fatality is rare but children are at high risk during myasthenia crisis.

AB - Juvenile myasthenia gravis is a chronic autoimmune disorder which occurs when serum antibodies combine with nicotinic acetylcholine receptors at the muscle membrane of the motor endplate imparing the neuromuscular transmission. It results in early muscle fatigability with progression to a complete paralysis during repetitive muscle contraction (movements) or steady muscle contraction (postures), and less common persistent paralysis at rest. The cranial nerves, mainly the one innervating the extraoccular and palpebral levator, are the most susceptible to permanent weakness and paralysis at rest. Initial clinical presentations are generalized, ocular and respiratory forms. The diagnosis is suspected through medical history of abnormal fatigability and corroborated by physical examination, repetitive nerve stimulation of an affected but not complete paralyzed muscle, correction of fatigability by the intravenous administration of acetylcholine esterase inhibitors, and by the presence of serum acetylcholine receptors antibodies (ACRA). The long term treatment is symptomatic (acetylcholine inhibitors) and etiopathogenic (immunosupresor drugs, plasmapheresis, intravenous gamma globulin and thymectomy. Spontaneous or post symptomatic and etiopathogenic treatment remissions occur from 1 to 10 years. Fatality is rare but children are at high risk during myasthenia crisis.

KW - ACRA

KW - Diagnosis

KW - Myasthenia gravis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=62149096420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62149096420&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 71

EP - 83

JO - Medicina

JF - Medicina

SN - 0025-7680

IS - 1 PART 1

ER -